International law firm, Gowling WLG, has advised biopharmaceutical firm, Dynavax Technologies Corporation, on their commercialisation agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany.
In February 2021, the European Commission (EC) granted marketing authorization for HEPLISAV B for the active immunization against hepatitis B virus infection (HBV) caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. Hepatitis B is a highly infectious and potentially deadly virus with increasing infection rates, and over 250 million people infected worldwide – but can be prevented with effective vaccination.
Gowling WLG commercial partner, David Lowe, advised on the agreement with Bavarian Nordic, working closely with Riccardo Manetti, Dynavax's Vice President, Business Development. David is a member of Gowling WLG's life sciences sector team which is as renowned for its technical abilities as it is for its legal expertise. Whether protecting and enforcing intellectual property rights, structuring transactions to mitigate risk or going through a merger and acquisition, the team helps life sciences companies realise their business objectives.
Commenting, David Lowe said:
"Our deep experience in the life sciences sector but also international commercialisation and distribution agreements put us in a great place to support Dynavax in securing this strategically important arrangement for German commercialisation."
"Playing a role in bringing such a vital healthcare offering to life is important to us - we have been really pleased to work with Dynavax to help them roll out this important vaccine."